News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Inhibitex, Inc. (INHX), in Connection with the Sale of the Company to Bristol-Myers Squibb Company (BMY)


1/11/2012 6:08:27 AM

NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky is investigating the Board of Directors of Inhibitex, Inc. (“Inhibitex” or the “Company”) (Nasdaq: INHX) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Bristol-Myers Squibb Co. (NYSE: BMY). Under the terms of the transaction, Inhibitex shareholders will receive $26 per share of Inhibitex stock they own. The transaction has a total approximate value of $2.5 billion. Shareholders with beneficial ownership of approximately 17% of Inhibitex common stock have already entered into agreements with Bristol-Myers to support the transaction and to tender their shares in the tender offer.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES